In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ImmunoGen adds Merck's Keytruda to its ovarian cancer trials

Executive Summary

ImmunoGen Inc. and Merck & Co. Inc. entered into an trial collaboration to investigate the combination of Merck's marketed immunotherapy Keytruda (pembrolizumab) with Immunogen's mirvetuximab soravtansine for ovarian cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations

Related Companies